Initial Gene-Editing Trials Show Positive Results In Treating Blood Diseases
Dhir Acharya - Nov 22, 2019
CRISPR Therapeutics and Vertex developed an investigational therapy called CTX001 that uses gene-editing tech CRISPR to edit stem cells in the human body.
- Scientists Create Mouse Chimeras With Cancer Resistance That Live 25 Percent Longer
- The Transgenic Fungus Delivered From Spider Venom Will Help Kill Mosquitoes
- Scientists Now Able To Modify Gene That Makes Us Ugly And Fat
CRISPR Therapeutics along with Vertex has developed an investigational therapy called CTX001 that uses gene-editing tech CRISPR to edit stem cells in the human body. The treatment has given promising initial results to two patients with inherited blood diseases. Preliminary results suggest that this therapy is safe and sets the foundation for further trials of this new treatment.
The patients in question have different hemoglobinopathies, the disorders affecting a protein called hemoglobin that carries O2 around the body. The first patient is from the US, having sickle cell disease that generates misshapen red blood cells that are sickle-shaped. The patient started receiving the treatment this April. The second patient is from Europe, who has beta-thalassemia, which reduces the amount of hemoglobin generated. This patient has been treated for nine months.
Patients with sickle cell disease suffer from painful crises when the sickle-shaped red blood cells block blood vessels. Meanwhile, patients who have beta-thalassemia need constant blood transfusions so that the hemoglobin levels in their bodies are properly managed.
After receiving the treatment, the first patient no longer had painful crises while the second one no longer required blood transfusions.
In a Tuesday press release, CRISPR Therapeutics CEO Samarth Kulkarni said that:
The treatments are not cheap or easy to carry out. They need health care professionals for collecting stem cells from patients’ blood before editing them using CRISPR, outside the body. In this gene-editing technology, a version of the hemoglobin gene is activated, which is normally deactivated in adults. In addition, the patients receive the edited gene through a stem cell transplant. Once the patient has received the cells, they are expected to create shop in the bone marrow then start to pump out adequate amounts of hemoglobin.
Vertex and CRISPR Therapeutics expect to enroll 45 patients from Europe, Canada, and the US in CTX001 trials, each of whom will receive long-term follow-up study for the treatment’s safety assessment.
Over the past year, CRISPR has been talked about a lot as scientists take ethical and moral concerns into account with the ability to edit the human gene. Last November, scientist He Jiankui from China revealed that he had used CRISPR to edit human embryos, which generated a gene-edited pair of twins. The scientific community slammed the conduct, calling to stop human gene editing, which has gathered steam gradually throughout this year.
However, this technology has also been known as a way to bring back extinct species or terminate an entire species of mosquitoes that carries malaria. And while ethicists and scientists are struggling with considerations, researchers are working to create more impressive, innovative techs to manipulate DNA with high accuracy. The CTX001 may unlock a new era for gene therapy.